← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksACRSEarnings History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

ACRS logoAclaris Therapeutics, Inc. (ACRS) Earnings History

Annual and quarterly earnings data from 2013 to 2025

TTM Net Income
-$65M
Net Loss
TTM EPS
$-0.53
Diluted
YoY EPS Growth
+69.0%
Excellent
Net Margin
-829.6%
Profitability
Operating Margin-975.9%
Gross Margin73.3%
ROE-50.2%
ROA-34.1%
Highest Annual Net Income-$5M (2013)
Highest Quarterly EPS$-0.02 (Q4 2023)
Consecutive Profitable Years0 years
Q4 2025
Net Income-$20M
EPS$-0.16
QoQ Growth-35.5%Declining

Loading earnings history...

ACRS EPS Growth (CAGR)

Compound annual growth rate of diluted earnings per share

1-Year
N/A
N/M
3-Year
N/A
N/M
5-Year
N/A
N/M
10-Year
N/A
N/M

CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.

ACRS Profitability Analysis

Margin trends over time

View revenue breakdown →
YearGross MarginOperating MarginNet Margin
202573.3%-975.9%-829.6%
202485.1%-758.2%-705.5%
202342.1%-311.6%-283.1%
202259.8%-302.0%-292.1%
202130.3%-1327.1%-1344.0%
Gross Margin = Gross Profit ÷ Revenue
Operating Margin = Operating Income ÷ Revenue
Net Margin = Net Income ÷ Revenue

Download Data

Export ACRS earnings history in CSV or JSON format

Free sign-in required to download data

Aclaris Therapeutics, Inc. (ACRS) Earnings Overview

As of May 8, 2026, Aclaris Therapeutics, Inc. (ACRS) reported trailing twelve-month net income of -$65M, reflecting +69.0% year-over-year growth. The company earned $-0.53 per diluted share over the past four quarters, with a net profit margin of -829.6%.

Looking at the long-term picture, ACRS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2013.

Aclaris Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NKTR (-$164M net income, -297.1% margin), PTGX (-$115M net income, -282.8% margin), DAWN (-$107M net income, -67.8% margin), ACRS has room to improve margins relative to the peer group. Compare ACRS vs NKTR →

ACRS Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ACRS logoACRSCurrent
-$65M$-0.53-829.6%-50.2%+69.0%—
NKTR logoNKTR
-$164M$-8.08-297.1%-217.9%-12.1%
PTGX logoPTGX
-$115M$-1.63-282.8%-20.2%-148.5%
DAWN logoDAWN
-$107M$-1.04-67.8%-22.7%-2.0%
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
DERM logoDERM
-$9M$-0.38-26.1%-72.6%-242.9%
Best in group
Lowest in group

ACRS Historical Earnings Data (2013–2025)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$65M+50.8%-$76M$-0.53-829.6%-975.9%
2024-$132M-49.3%-$142M$-1.71-705.5%-758.2%
2023-$88M-1.8%-$97M$-1.27-283.1%-311.6%
2022-$87M+4.4%-$90M$-1.33-292.1%-302.0%
2021-$91M-78.1%-$90M$-1.60-1344.0%-1327.1%
2020-$51M+68.4%-$51M$-1.20-787.0%-785.4%
2019-$161M-21.6%-$111M$-3.46-3817.2%-2627.3%
2018-$133M-93.7%-$135M$-4.03-1315.4%-1341.9%
2017-$69M-42.5%-$72M$-2.44-4071.5%-4303.2%
2016-$48M-133.8%-$49M$-2.25--

See ACRS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ACRS Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare ACRS vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

ACRS — Frequently Asked Questions

Quick answers to the most common questions about buying ACRS stock.

Is ACRS growing earnings?

ACRS EPS is $-0.53, with earnings growth accelerating to +69.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-65M.

What are ACRS's profit margins?

Aclaris Therapeutics, Inc. net margin is -829.6%, with operating margin at -975.9%. Below-average margins reflect competitive or cost pressures.

How consistent are ACRS's earnings?

ACRS earnings data spans 2013-2025. The accelerating earnings trend is +69.0% YoY. Historical data enables comparison across business cycles.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

ACRS Earnings Over Time (2014–2025)

Net income and EPS trends